Evaluating a Community-Driven Cervical Cancer Prevention Strategy in Western Kenya
Cervical cancer impacts over half a million women globally each year. While cervical cancer control in wealthy countries is one of the public health success stories of the past century, the disease remains a significant threat for women in developing countries where almost 90% of cases occur. Although effective screening technologies have been developed for use in low-resource settings, there are complicated, context-specific barriers to their implementation as part of a complete cervical cancer prevention strategy. In addition to employing evidence-based screening and treatment techniques, the overall population impact of cervical cancer screening depends on two main factors:
1. community-wide access to screening and
2. successful linkage to treatment or follow-up for women who screen positive.
Strategies to address these factors must also be acceptable, relatively easy to implement, and cost-effective to be sustainable.
Our formative work in western Kenya, a country with a high cervical cancer burden, uncovered tangible barriers and facilitators to these key steps in the "cervical cancer prevention cascade" and has led to a strategy that will increase women's uptake of cervical cancer prevention activities.
Based on this work, we have developed the following hypotheses
1. cervical cancer screening with self-collected human papillomavirus (HPV) specimens will reach more women when offered through community health campaigns versus government clinics; and
2. community-developed strategies will successfully link more women to treatment than the current standard of care (i.e., referral to treatment sites).
To test these hypotheses, we will work with our local implementing partners, the Kenya Medical Research Institute, and the RCTP-FACES NSO to carry out a two-phase cluster-randomized trial of implementation strategies for a Ministry of Health and WHO-recommended cervical cancer prevention protocol in western Kenya. During Phase 1, communities will be randomized to HPV-testing in either community-health campaigns or in clinics, with standard referral for treatment of HPV women to government facilities. We will use the RE-AIM framework, a framework used to evaluate implementation strategies, (Reach, Efficacy, Adoption, Implementation consistency and costs, and Maintenance) to assess the key outcomes; we will then work in partnership with the community to develop a strategy for enhanced linkage to care. In Phase 2, all communities will offer community-based testing with enhanced linkage to care. Conducting this cluster-randomized trial will enable us to assess the proportion of women in each community who get cervical cancer screening, the gain in treatment access with enhanced linkage to care, and the cost-effectiveness of the two interventions. The RE-AIM framework will allow us to measure and refine the context-specific dimensions of the project to produce a tool-kit for scale-up within this region and implementation into similar settings.